BeyondSpring Inc.
BYSI
Rank in Stocks
#25527
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on... BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Share Price
$0.617
Last synced: 2026-11-09
Market Cap
$25.37M
Change (1 day)
-1.44%
Change (1 year)
-71.95%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BeyondSpring Inc. (BYSI)
Category
Healthcare
EPS for BeyondSpring Inc. (BYSI)
EPS as of June 2026 TTM: $-0.17
According to BeyondSpring Inc.'s latest financial reports, its current EPS (TTM) is $-0.17. At the end of 2025 the company had an EPS of $-0.20, an increase over its 2024 EPS of $-0.28.
EPS history for BeyondSpring Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.17 | -15.00% |
| 2025 | $-0.20 | -28.57% |
| 2024 | $-0.28 | -48.15% |
| 2023 | $-0.54 | -36.47% |
| 2022 | $-0.85 | -48.17% |
| 2021 | $-1.64 | -19.61% |
| 2020 | $-2.04 | 31.61% |
| 2019 | $-1.55 | -35.95% |
| 2018 | $-2.42 | -45.00% |
| 2017 | $-4.40 | 486.67% |
| 2016 | $-0.75 | 41.51% |
| 2015 | $-0.53 | 178.95% |
| 2014 | $-0.19 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -9,311.76% |
US
|
|
| $-7.07 | 4,058.82% |
US
|
|
| $-5.29 | 3,011.76% |
AU
|
|
| $12.88 | -7,676.53% |
BE
|
|
| $21.56 | -12,782.35% |
NL
|
Questions about BeyondSpring Inc.'s earnings per share (EPS)
What is BeyondSpring Inc.'s earnings per share (EPS)?
BeyondSpring Inc.'s earnings per share (EPS) over the last twelve months is $-0.17, as of Jun 2026.
What was BeyondSpring Inc.'s earnings per share (EPS) in 2025?
In 2025, BeyondSpring Inc.'s earnings per share (EPS) was $-0.20, compared with $-0.28 in 2024.
How has BeyondSpring Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BeyondSpring Inc.'s earnings per share (EPS) was highest in 2025 ($-0.20) and lowest in 2020 ($-2.04).
How does BeyondSpring Inc.'s earnings per share (EPS) compare with similar companies?
BeyondSpring Inc.'s earnings per share (EPS) ($-0.17) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.